List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
In this article, David Bardsley, Commercial Director, and Nick Foster, Vice President of Discovery CRO at Cresset, explore the challenges that occur when approaching drug discovery in silos and how harnessing advances in technology can help to overcome them.
New understanding of “Christchurch mutation” in the APOE gene may lead to novel Alzheimer's disease treatments.
Researchers find that polymerase epsilon exonuclease is an essential target for cancer diagnosis and treatments that rely on DNA damage.
Fatty liver disease treatments may become more effective after identification and greater understanding of more drug targets.
Excessive insulin levels in people with obesity and type 2 diabetes overstimulates pancreatic cells, initiating disease.
Researchers have been able to customise nanoparticles to target biological entities, like tumours and viruses.
Short-chain fatty acids produced by intestinal bacteria initiate dendritic elongation, a mechanism that could be used as a drug target.
Scientists have discovered the motor protein dynein commands movement of cancer cells in soft tissue models, offering new clinical targets.
Researchers have discovered a molecule that binds to a cancer cell protein, stopping growth of breast and ovarian tumours.
Researchers found surprising function of pulmonary ionocytes which may affect how cystic fibrosis drugs work.
In this interview, Anne Neville, Director at Microbiotica, elaborates on the significance of the Microbiotica Culture Collection (MCC) and Microbiotica Reference Genome Database (MRGD), which are fundamental to the development of live biotherapeutic medicines.
New research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany, has highlighted a previously underestimated aspect of acne's impact on individuals: its profound influence on social perception.
In an exclusive interview with Nikki Carter at Molecular Devices, we explore the the power of patient-derived organoids (PDOs) in drug discovery.
![In experiments in rats and mice, two Johns Hopkins scientists -- an engineer and an ophthalmologist -- report the successful use of nanoparticles to deliver gene therapy for blinding eye disease. A uniquely engineered large molecule allows researchers to compact large bundles of therapeutic DNA to be delivered into the cells of the eye [credit: John Hopkins Medicine].](https://www.drugtargetreview.com/wp-content/uploads/nanoparticle-gene-therapy-blindness-image.jpg)
This article discusses the need for adulticidal drugs to treat Onchocerca volvulus infections, a parasite causing onchocerciasis (river blindness), as the current treatment with ivermectin and surgery presents challenges for affected communities. It highlights research findings on the potential of analgesic medicines to target adult worms and emphasises the importance…
Infectious agents' drug resistance is a complex challenge affecting survival. Understanding their mechanisms in vectors, the potential of plant-derived treatments, and roles of nucleic acids and biochemical compounds is crucial for effective therapy, requiring collaborative international research through the One Health Initiative.
